| Product Name |
Vesicular Stomatitis Virus (VSV) Pseudotyped with SARS-CoV-2 Spike Glycoprotein, HexaPro Variant |
| Catalog Number |
EG-351 |
| Description |
Vesicular stomatitis virus (VSV) particles pseudotyped with SARS-CoV-2 spike glycoprotein (Wuhan-Hu-1, GenBank: QHD43416.1), stabilized as a trimer (HexaPro variant) with mutations (RRAR682–685GSAS, F817P, A892P, A899P, A942P, K986P, V987P) to maintain an antigenically optimal prefusion conformation, produced in HEK293T cells, purified by ultracentrifugation, expressing EGFP as a reporter. |
| Mutations |
RRAR682–685GSAS, F817P, A892P, A899P, A942P, K986P, V987P |
| Source |
HEK293T cells |
| Reporter |
EGFP |
| Applications |
- Screening SARS-CoV-2 neutralizing antibodies
- Assessing vaccine efficacy
|
| Titer |
>1 × 107 RFU/mL or >1 × 105 TU/mL |
| Storage |
-80°C |
| Shipping |
Dry ice |
| References |
- Whitt, M. A. (2010). Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. Journal of Virological Methods, 169(2), 365–374. doi:10.1016/j.jviromet.2010.08.006.
- Zost, S. J., et al. (2020). Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein. Scientific Reports, 10, 19076. doi:10.1038/s41598-020-76135-w.
|
|